Prof Stephen Mulligan speaks with ecancertv at BSH 2016 about the turning tides of chronic lymphocyctic leukaemia.

With a consideration of the recent past, from novel treatment combinations that are extending patient survival up to four fold, to modern molecular understanding of the micro-environemnt, Dr Mulligan identifies upcoming trials he anticipates will continue to move survival rates forward.

ecancer's filming at ICMM 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.